Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer

2.

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

3.

Cancerous breast tissue glows in new AI-enhanced MRI images

4.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

5.

enhancing survivors of brain tumors' quality of life.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot